<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Marban E</submitter><funding>NHLBI NIH HHS</funding><pagination>877-885</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11469554</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>135(8)</volume><pubmed_abstract>All Food and Drug Administration-approved noncoding RNA (ncRNA) drugs (n≈20) target known disease-causing molecular pathways by mechanisms such as antisense. In a fortuitous evolution of work on regenerative medicine, my coworkers and I inverted the RNA drug discovery process: first we identified natural disease-modifying ncRNAs, then used them as templates for new synthetic RNA drugs. Mechanism was probed only after bioactivity had been demonstrated. The journey began with the development of cardiosphere-derived cells (CDCs) for cardiac regeneration. While testing CDCs in a first-in-human trial, we discovered they worked indirectly: ncRNAs within CDC-secreted extracellular vesicles mediate the therapeutic benefits. The vast majority of such ncRNAs are fragments of unknown function. We cho</pubmed_abstract><journal>Circulation research</journal><pubmed_title>Deconstructing Regenerative Medicine: From Mechanistic Studies of Cell Therapy to Novel Bioinspired RNA Drugs.</pubmed_title><pmcid>PMC11469554</pmcid><funding_grant_id>R01 HL155346</funding_grant_id><funding_grant_id>R01 HL167921</funding_grant_id><funding_grant_id>R01 HL164588</funding_grant_id><funding_grant_id>R01 HL142579</funding_grant_id><funding_grant_id>R01 HL168296</funding_grant_id><pubmed_authors>Marban E</pubmed_authors></additional><is_claimable>false</is_claimable><name>Deconstructing Regenerative Medicine: From Mechanistic Studies of Cell Therapy to Novel Bioinspired RNA Drugs.</name><description>All Food and Drug Administration-approved noncoding RNA (ncRNA) drugs (n≈20) target known disease-causing molecular pathways by mechanisms such as antisense. In a fortuitous evolution of work on regenerative medicine, my coworkers and I inverted the RNA drug discovery process: first we identified natural disease-modifying ncRNAs, then used them as templates for new synthetic RNA drugs. Mechanism was probed only after bioactivity had been demonstrated. The journey began with the development of cardiosphere-derived cells (CDCs) for cardiac regeneration. While testing CDCs in a first-in-human trial, we discovered they worked indirectly: ncRNAs within CDC-secreted extracellular vesicles mediate the therapeutic benefits. The vast majority of such ncRNAs are fragments of unknown function. We cho</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Sep</publication><modification>2026-06-03T20:23:40.007Z</modification><creation>2026-05-01T03:10:14.392Z</creation></dates><accession>S-EPMC11469554</accession><cross_references><pubmed>39325847</pubmed><doi>10.1161/CIRCRESAHA.124.323058</doi><doi>10.1161/circresaha.124.323058</doi></cross_references></HashMap>